Trastuzumab deruxtecan is a complex antibody-drug conjugate classified as a HER2-targeted immunotherapy, primarily utilized in the treatment of unresectable or metastatic HER2-positive breast cancer, as… Read more
Trastuzumab deruxtecan is a complex antibody-drug conjugate classified as a HER2-targeted immunotherapy, primarily utilized in the treatment of unresectable or metastatic HER2-positive breast cancer, as well as specific cases of gastric and non-small cell lung cancer. Accurate analysis of this therapeutic agent requires high-quality reference materials to ensure safety and efficacy throughout the development lifecycle. This category features critical analytical tools, including Trastuzumab deruxtecan reference standards, along with essential pharmacopeial and non-pharmacopeial impurities, metabolites, and stable isotope-labelled compounds. Pharmaceutical laboratories rely on these diverse standards to conduct rigorous impurity profiling, validate analytical methods, and perform precise quality control testing. By utilizing these materials, researchers can effectively monitor degradation pathways and quantify trace components, ultimately supporting the stringent regulatory requirements necessary for the characterization and assessment of this advanced biologic medication.